Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer
Zhen Zeng, Anastasia Gandini, Rituparna Bhatt…·Brian G. Gabrielli
This study evaluates CHK1i+LDHU therapy in HGSOC, showing it kills cancer cells and reprograms the tumor microenvironment to enhance anti-tumor immune responses.